Early Inflammatory Bowel Disease Progression

Launched by PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE · Dec 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the bacteria and other microorganisms in the gut may help predict how Inflammatory Bowel Disease (IBD) progresses in patients during the first year after they are diagnosed. IBD includes conditions like Crohn's Disease and Ulcerative Colitis, which can cause symptoms such as diarrhea, abdominal pain, and rectal bleeding. The researchers hope to understand if the makeup and function of gut microbes can give insights into how a patient’s condition might change over time.

To participate in this study, adults aged 18 to 80 who have been experiencing gastrointestinal symptoms for at least three weeks may be eligible. However, those with confirmed infections in the gastrointestinal tract will not be included. Participants can expect to provide samples for testing and may undergo assessments to help researchers track their health over the course of the trial. This study is currently recruiting participants, and joining could help improve understanding and treatment of IBD for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with with at least 3 weeks of gastrointestinal symptoms including diarrhea, rectal bleeding, abdominal pain, tenesmus or urgency
• Exclusion Criteria:
• • Confirmed infectious disease of the gastrointestinal tract